See Me is a B2B platform that utilizes an ANVISA-approved self-collection device and PCR analysis for less invasive gynecological diagnostics, focusing on the evaluation of vaginal microbiome, STIs, HPV, and recurrent vulvovaginitis. The platform streamlines patient navigation and automates therapeutic plans, enabling gynecologists to provide precise diagnoses and tailored treatments more efficiently.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional gynecological diagnostics often involve invasive procedures and may lack the precision needed for early detection and tailored treatment of vaginal health issues. This can lead to delayed diagnoses and less effective management of conditions such as vaginal microbiome imbalances, sexually transmitted infections (STIs), human papillomavirus (HPV), and recurrent vulvovaginitis.
Solution
See Me offers a B2B platform that provides gynecologists with a less invasive and more precise approach to gynecological diagnostics. The platform utilizes an ANVISA-approved self-collection device and PCR analysis to evaluate the vaginal microbiome, screen for STIs and HPV, and identify the causes of recurrent vulvovaginitis. By integrating guided tracking, patient navigation, and automated therapeutic plans, See Me enables clinicians to deliver personalized treatment plans based on advanced diagnostic insights. The platform aims to streamline the diagnostic process, improve patient management, and enhance the overall effectiveness of gynecological care.
Target Audience
See Me primarily targets gynecologists and clinics seeking to improve the precision, efficiency, and patient experience of gynecological diagnostics and treatment.
Features
- ANVISA-approved self-collection device for less invasive sample collection
- PCR analysis for accurate detection of vaginal microbiome composition, STIs, and high-risk HPV strains (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 e 68)
- Guided patient tracking and navigation within the healthcare service
- Automated generation of reports and follow-up plans
- Integration of advanced protocols for the pathology of the lower genital tract (PTGI)
- Identification of Lactobacillus species, Candida (albicans and non-albicans), and bacteria associated with vaginosis
- Support for personalized treatment plans with prebiotics and probiotics